DAB389IL2 (ONTAK®) fusion protein therapy of chronic lymphocytic leukaemia

Expert Opinion on Biological Therapy

Volumn 3, Issue 1, 2003, Pages 179-186

  Frankel, Arthur E ^a   Fleming, Donald R ^b   Powell, Bayard L ^a   Gartenhaus, Ronald ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Medical Center of Vincennes   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chronic lymphocytic leukemia; Diphtheria fusion protein; Interleukin 2 receptor

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALLOPURINOL; AMINOTRANSFERASE; BEXAROTENE; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CREATINE KINASE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; FLUDARABINE; HYBRID PROTEIN; INFUSION FLUID; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 7; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OMEPRAZOLE; PARACETAMOL; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA; DIPHTHERIA TOXIN;

AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CAPILLARY LEAK SYNDROME; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG STRUCTURE; DRUG TARGETING; DYSPNEA; EDEMA; FATIGUE; FEVER; GENE EXPRESSION; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; MALAISE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; UREMIA; VOMITING; AGED; ANIMAL; CHEMISTRY; FEMALE; MALE; METABOLISM; MIDDLE AGED; PILOT STUDY;

AGED; ANIMALS; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS;

EID: 0037322572     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/eobt.3.1.179.20959     Document Type: Review

References (57)

1. ZENT CS, KYASA MJ, EVANS R, SCHICHMAN SA: Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer (2001) 92:1325-1330.
2. KLEIN U, TU Y, STOLOVITZKY GA et al.: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. (2001) 194:1625-1638.
3. STILGENBAUER S, BULLINGER L, LICHTER P, DOHNER H: Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia (2002) 16:993-1007.
4. TSUKADA N, BURGER JA, ZVAIFLER NJ, KIPPS TJ: Distinctive features of 'nurselike' cells that differentiate in the context of chronic lymphocytic leukemia. Blood (2002) 99:1030-1037.
5. ROZMAN C, MONTSERRAT E: Chronic lymphocytic leukemia. N. Eng. J. Med. (1995) 333:1052-1057.
6. DIRAIMONDO F, ALBITAR M, HUH Y et al.: The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer (2002) 94:1721-1730.
7. DHODAPKAR M, TEFFERI A, SU J, PHYLIKY RL: Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study. Leukemia (1993) 7:1232-1235.
8. HAN T, BARCOS M, EMRICH L et al.: Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data. J. Clin. Oncol. (1984) 2:562-570.
9. STRATOWA C, LOFFLER G, LICHTER P et al.: cDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int. J. Cancer (2001) 91:474-480.
10. FADERL S, KEATING MJ, DO KA et al.: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia. Leukemia (2002) 16:1045-1052.
11. OSCIER DG, GARDINER AC, MOULD SJ et al.: Multivariate analysis of prognostic factors in CLL: clinical stage, IgVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood (2002) 100:1177-1184.
12. CONSOLI U, SANTONOCITO A, STAGNO F et al.: Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br. J. Haematol. (2002) 116:774-780.
13. DONEY KC, CHAUNCEY T, APPELBAUM FR: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant. (2002) 29:817-823.
14. KHOURI IF, KEATING MJ, SALIBA RM, CHAMPLIN RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy (2002) 4:217-221.
15. DREGER P, MONTSERRAT E: Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia (2002) 16:985-992.
16. CHESON BD, BENNETT JM, GREVER M et al.: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 87:4990-4997.
17. RAI K, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Eng. J. Med. (2000) 343:1750-1757.
18. SCHMITT B, WENDTNER CM, BERGMANN M et al.: Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin. Lymphoma (2002) 3:26-35.
19. LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768-773.
20. KEATING MJ, O'BRIEN S, ALBITAR M: Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin. Oncol. (2002) 29(Suppl. 2):70-74.
21. NABHAN C, ROSEN ST: Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin. Oncol. (2002) 29(Suppl. 2):75-80.
22. KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554-3561.
23. KENNEDY B, RAWSTRON A, CARTER C et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 99:2245-2247.
24. O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. (2001) 19:2165-2170.
25. BYRD JC, MURPHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. (2001) 19:2153-2164.
26. PERKINS JG, FLYNN JM, HOWARD RS, BYRD JC: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer (2002) 94:2033-2039.
27. FRANKEL AE, POWELL BL, VALLERA DA, NEVILLE DM: Chimeric fusion proteins-diphtheria toxin-based. Curr. Opin. Invest. Drugs (2001) 2:1294-1301.
28. ELLERY JM, NICHOLLS PJ: Alternate signaling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev. (2002) 3:27-40.
29. WEISS LM, MICHIE SA, MEDEIROS LJ, STRICKLER JG, GARCIA CF, WARNKE RA: Expression of Tac antigen by non-Hodgkin's lymphomas. Am. J. Clin. Pathol. (1987) 88:483-485.
30. ROSOLEN A, NAKANISHI M, POPLACK DG et al.: Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. Blood (1989) 73:1968-1972.
31. DAMLE RN, GHIOTTO F, VALETTO A et al.: B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood (2002) 99:4087-4093.
32. TSILIVAKOS V, TSAPIS A, KOKOLYRIS S, ILIAKIS P, PERRAKI M, GEORGOULIAS V: Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. Leukemia (1994) 8:1571-1578.
33. NAKASE K, KITA K, NASU K et al.: Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am. J. Hematol. (1994) 46:179-183.
34. SHEIBANI K, WINBERG CD, VAN DE VELDE S, BLAYNEY DW, RAPPAPORT H: Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am. J. Pathol. (1987) 127:27-37.
35. CHOE S, BENNETT MJ, FUJII G et al.: The crystal structure of diphtheria toxin. Nature (1992) 357:216-222.
36. BROOKE JS, CHA JH: Molecular characterization of key diphtheria toxin: receptor interactions. Biochem. Biophys. Res. Commun. (2000) 275:374-381.
37. SIMPSON JC, SMITH DC, ROBERTS LM, LORD JM: Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin. Exp. Cell Res. (1998) 239:293-300.
38. FALNES PO, SANDVIG K: Penetration of protein toxins into cells. Curr. Opin. Cell. Biol. (2000) 12:407-413.
39. BELL CE, EISENBERG D: Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry (1996) 35:1137-1149.
40. VAN DERSPEK JC, MURPHY JR: Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells. Methods Enzymol. (2000) 327:239-249.
41. WILLIAMS DP, SNIDER CE, STROM TB, MURPHY JR, Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. (1990) 265:11885-11889.
42. 389IL-2 in cultured hematopoietic cells. Cancer Res. (1996) 56:2590-2595.
43. BACHA PA, FORTE SE, MCCARTHY DM, ESTIS L, YAMADA G, NICHOLS JC: Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. Int. J. Cancer (1991) 49:96-101.
44. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 91:399-405.
45. OLSEN E, DUVIC M, FRANKEL A et al.: Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. (2001) 19:376-388.
46. FOSS FM, BACHA P, OSANN KE, DEMIERRE MF, BELL T, KUZEL T: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma (2001) 1:298-302.
47. RAILAN D, FIVENSON DP, WITTENBERG G: Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. (2000) 43:323-324.
48. ACOSTA M, TEITELBAUM A: Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. (2001) 44:312-313.
49. Ontak Package Insert (1999). San Diego, CA: Ligand Pharmaceuticals, Incorporated; February 5, 1999.
50. TALPUR R, APISARNTHANARAX N, WARD S, DUVIC M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk. Lymphoma (2002) 43:121-126.
51. GORGUN G, FOSS F: Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood (2002) 100:1399-1403.
52. NAKASE K, KITA K, SHIRAKAWA S, TANAKA I, TSUDO M: Induction of cell surface interleukin 2 receptor alpha chain expression on non-T lymphoid leukemia cells. Leuk. Res. (1994) 18:855-859.
53. DECKER T, HIPP S, KREITMAN RJ, PASTAN I, PESCHEL C, LICHT T: Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood (2002) 99:1320-1326.
54. DIGEL W, SCHMID M, HEIL G, CONRAD P, GILLIS S, PORZSOLT F: Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood (1991) 78:753-579.
55. TRENTIN L, ZAMBELLO R, AGOSTINI C et al.: Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood (1994) 84:4249-4256.
56. BAMBOROUGH P, HEDGECOCK CJ, RICHARDS WG: The interleukin-2 and interleukin-4 receptors studied by molecular modelling. Structure (1994) 2:839-851.
57. THORNTON PD, HAMBLIN M, TRELEAVEN JG, MATUTES E, LAKHANI AK, CATOVSKY D: High dose methylprednisolone in refractory chronic lymphocytic leukemia. Leuk. Lymphoma (1999) 34:167-170.